Publications

Search our bibliography using the filters on the right-hand side.

Displaying 301 through 350 of 467 publications.

Ellison RC, Rothman KJ, Zhang Y, Djousse L. Cardiovascular risk factors and confounders among nondrinking and moderate-drinking U.S. adults. Am J Prev Med. 2005 Oct 1;29(3):243.

Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA, O'Brien BJ, Torti FMJr, Tsiatis AA, Wilan AR, Mark DB, Schulman KA. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J. 2005 Mar;149(3):434-43.

Talmud PJ, Stephens JW, Hawe E, Demissie S, Cupples LA, Hurel SJ, Humphries SE, Ordovas JM. The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet. 2005;69(6):613-22.

Li P, Elrayess MA, Gomma AH, Palmen J, Hawe E, Fox KM, Humphries SE. The microsatellite polymorphism of heme oxygenase-1 is associated with baseline plasma IL-6 level but not with restenosis after coronary in-stenting. Chin Med J (Engl). 2005;118(18):1525-32.

Li P, Sanders J, Hawe E, Brull D, Montgomery H, Humphries S. Inflammatory response to coronary artery bypass surgery: does the heme-oxygenase-1 gene microsatellite polymorphism play a role? Chin Med J (Engl). 2005;118(15):1285-90.

Ireland H, Konstantoulas CJ, Cooper JA, Hawe E, Humphries SE, Mather H, Goodall AH, Hogwood J, Juhan-Vague I, Yudkin JS, Di Minno G, Margaglione M, Hamsten A, Miller GJ, Bauer KA, Kim YT, Stearns-Kurosawa DJ, Kurosawa S. EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis. 2005;183(2):283-92.

Morange PE, Saut N, Alessi MC, Frere C, Hawe E, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Humphries SE, Juhan-Vague I, HIFMECH Study Group. HIFMECH Study Group. Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. Atherosclerosis. 2005;179(2):317-23.

Eriksson-Berg M, Deguchi H, Hawe E, Scanavini D, Orth-Gomér K, Schenck-Gustafsson K, Humphries SE, Silveira A, Hamsten A. Influence of factor VII gene polymorphisms and environmental factors on plasma coagulation factor VII concentrations in middle-aged women with and without manifest coronary heart disease. Thromb Haemost. 2005;93(2):351-8.

Pladevall-Vila M, Elston Lafata J, Tunceli K, Divine G, Simpkins J, Williams LK. Racial disparities in lipid management in patients with diabetes. Presented at the Joint Meeting of the Society for Epidemiologic Research and Canadian Society for Epidemiology and Biostatistics; 2005.

Pladevall-Vila M, Brotons C, Gabriel R. The com99 study results: a cluster-randomized trial of an intervention to improve adherence to antihypertensive drugs among patients at high cardiovascular risk. Poster presented at the Fifteenth European Meeting on Hypertension; 2005.

Mannila MN, Silveira A, Hawe E, Eriksson P, Aillaud MF, Juhan-Vague I, Yudkin J, Margaglione M, Di Minno G, Mussoni L, Tremoli E, Humphries S, Hamsten A, HIFMECH Study Group. Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of beta-fibrinogen genotype and environmental factors. The HIFMECH Study. Thromb Haemost. 2004 Dec;92(6):1240-9.

Meads DM, Doughty NJ, McKenna SP, Doward LC, Pepke-Zaba J. Disease specific versus generic outcome assessment in pulmonary hypertension. Poster presented at the 2004 ISPOR 7th Annual European Congress; November 2004. Hamburg, Germany. [abstract] Value Health. 2004 Nov; 7(6):701-2.

Meads DM, McKenna SP, Doughty NJ, Doward LC, Pepke-Zaba J. Validation of the pulmonary hypertension outcome review (CAMPHOR) questionnaire. Poster presented at the 2004 ISPOR 7th Annual European Congress; November 2004. Hamburg, Germany. [abstract] Value Health. 2004 Nov; 7(6):700-1.

Gimeno V, Castellsague J, Maguire A, Eaton SC, McQuay LJ, Zhou X, Perez-Gutthann S. Gastrointestinal and cardiovascular characterization of users of valdecoxib and other cox-2 specific inhibitors. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(S1):S236.

Maguire A, Arellano Felix M, Perez-Gutthann S, Arana A. Risk benefit modeling: the use of stochastic simulation for safety evaluations. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S272.

Maguire A, Melero-Montes M, Saez-Lloret I, Varas-Lorenzo C, Perez-Gutthann S. Changes in hypokalemia and hyperkalemia between 1991 and 2000 in the US according to hypertensive status and treatment. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep; 13:S303.

Lafata JE, Pladevall-Vila M, Divine G, Ayoub M, Philbin EF. Are there race/ethnicity differences in outpatient congestive heart failure management, hospital use, and mortality among an insured population? Med Care. 2004 Jul;42(7):680-9.

Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, Di Minno G, Margaglione M, Tremoli E, Kooistra T, Morange PE, Lundman P, Mohamed-Ali V, Hamsten A, HIFMECH Study Group. HIFMECH Study Group. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism. 2004 Jul;53(7):852-7.

Varas-Lorenzo C, García-Rodriguez LA, Perez-Gutthann S. Use of oral steroids and the risk of acute myocardial infarction in the UK. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Jul; 13(S1):S6.

Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2004 Jul;148(1):122-8.

Anthony MS. Soy constituents and their role in cardiovascular disease prevention. Spring symposium continuing research in plants and human health. Presented at the Center for Plants and Human Health, University of Minnesota; May 12, 2004. Minneapolis, MN.

Bell TJ, Tang SS, Candrilli SD, Jamieson MJ. Evaluation of hypertension prevalence and blood pressure goal attainment using data from the 1999-2000 national health and nutrition examination survey (NHANES 1999-2000). Poster presented at the 19th Annual Scientific Meeting and Exposition of the American Society of Hypertension; May 2004.

Rodríguez S, Gaunt TR, O'Dell SD, Chen XH, Gu D, Hawe E, Miller GJ, Humphries SE, Day IN. Haplotypic analyses of the IGF2-INS-TH gene cluster in relation to cardiovascular risk traits. Hum Mol Genet. 2004 Apr;13(7):715-25.

Battleman DS, Candrilli SD, Burhani S, Peterson ED. Estimated prevalence of comorbid hypertension and dyslipidemia and therapeutic goal attainment among us adults in 2000, utilizing data from the national health and nutrition examination survey (NHANES III). Poster presented at the 16th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy; March 2004.

Konstantoulas C, Hawe E, Saut N, Yudkin JS, Di Minno G, Margaglione M, Hamsten A, Humphries SE, Juhan-Vague I, Ireland H, HIFMECH Study Group. Common variants in the thrombomodulin gene as a risk for myocardial infarction in the north of Europe (HIFMECH Study). Thromb Haemost. 2004 Mar;91(3):628-30.

Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.

Talmud PJ, Lewis SJ, Hawe E, Martin S, Acharya J, Marmot MG, Humphries SE, Brunner EJ. No APOEԑ4 effect on coronary heart disease risk in a cohort with low smoking prevalence: the Whitehall II study. Atherosclerosis. 2004;177(1):105-12.

Serrano NC, Casas JP, Díaz LA, Páez C, Mesa CM, Cifuentes R, Monterrosa A, Bautista A, Hawe E, Hingorani AD, Vallance P, López-Jaramillo P. Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study. J Clin Hypertens (Greenwich). 2004;44(5):702-7.

Maguire A, Melero-Montes M, Saez-Lloret I, Varas-Lorenzo C, Perez-Gutthann S. Changes in hypokalemia and hyperkalemia prevalence between 1991 and 2000 in the US according to hypertensive status and treatment. Pharmacoepidemiol Drug Saf. 2004;13:S303.

Elrayess MA, Webb KE, Bellingan GJ, Whittall RA, Kabir J, Hawe E, Syvänne M, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Miller GJ, Humphries SE. R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. Atherosclerosis. 2004;177(1):105-12.

Fenton M, Huang H, Hong Y, Hawe E, Kurz DJ, Erusalimsky JD. Early atherogenesis in senescence-accelerated mice. Exp Gerontol. 2004;39(1):115-22.

Kelberman D, Hawe E, Luong LA, Mohamed-Ali V, Lundman P, Tornvall P, Aillaud MF, Juhan-Vague I, Yudkin JS, Margaglione M, Di Minno G, Tremoli E, Humphries SE, HIFMECH Study Group. HIFMECH study group. Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study. Thromb Haemost. 2004;92(5):1122-8.

Plaza Cano MM, Garcia de Albeniz Martinez XA, de Andres Copa P, Braun Saro B, Suarez Alvarez C, Garcia de Aguinaga ML, Estirado de Cabo E, Guinea Esquerdo J, Posada de la Paz M. Diagnostic performance of echocardiography in the follow-up of patients with toxic oil syndrome. Rev Esp Cardiol. 2003 Dec;56(12):1195-201.

McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. Health-related quality of life in pulmonary arterial hypertension: results from a postal survey. Poster presented at the 10th Annual Conference of the International Society for Quality of Life Research (ISQOL); November 2003. [abstract] Qual Life Res. 2003 Nov; 12(7):836.

McKenna SP, Doughty N, Pepke-Zaba J, Meads D, Doward LC. Development of patient-reported outcome measures for pulmonary arterial hypertension. Poster presented at the 2003 ISPOR 6th Annual European Congress; November 2003. Barcelona, Spain. [abstract] Value Health. 2003 Nov; 6(6):671.

Doughty N, McKenna SP, Doward LC, Meads DM, Pepke-Zaba J. The impact of pulmonary arterial hypertension (PAH) on patients: results from qualitative patient interviews. Poster presented at the 10th Annual Conference of the International Society for Quality of Life Research (ISQOL); November 2003. [abstract] Qual Life Res. 2003 Nov; 12:814.

Fortuny J, Agusti A. Secondary prevention of acute myocardial infarction: should oral anticoagulants and platelet antiaggregants be administered on a combined basis? Med Clin (Barc). 2003 Oct 4;121(11):433-5. doi: 10.1016 / S0025-7753 (03) 73977-3

Miller GJ, Li P, Jones A, Humphries SE, Luong L, Payne JR, Montgomery HE, Hawe E, Dhamrait SS, Wootton PT, Toor IS. Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. J Clin Hypertens (Greenwich). 2003 Oct;42(4):500-6.

Gimeno V, Castellsague J, Varas-Lorenzo C, Hopkins JS, Eaton SC, Perez-Gutthann S. Gastrointestinal and cardiovascular characterization of users of COX-2 specific inhibitors. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):43.

Garcia-Rodriguez LA, Varas-Lorenzo C, Maguire A, Castellsague J, Gonzalez-Perez A, Perez-Gutthann S, Arellano A. Non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and the risk of acute myocardial infarction in the UK. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):117.

Varas-Lorenzo C, Maguire A, Perez-Gutthann S. Serum potassium levels, hypertension and antihypertensive treatment in the US adult population: NHANES III (1988-1994). Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):54.

Pladevall-Vila M, Williams K, Guyer H, Sadurni J, Falces C, Ribes A, Pare C, Brotons C, Gabriel R, Serrano-Rios M, Haffner S. The association between leptin and left ventricular hypertrophy: a population-based cross-sectional study. J Hypertens. 2003 Aug;21(8):1467-73.

Sapienza S, Sacco P, Floyd K, DiCesare J, Doan Q. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther. 2003 Jun;25(6):1872-87.

Reed SD, Friedman JY, Gnanasakthy A, Schulman KA. Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. Int J Technol Assess Health Care. 2003 Mar;19(2):396-406.

Djoussé L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Effect of serum albumin and bilirubin on the risk of myocardial infarction (The Framingham Offspring Study). Am J Cardiol. 2003 Feb 15;91(4):485-8.

Anthony MS. Red wine: ethanol versus polyphenols for cardiovascular disease prevention. Presented at the Purdue/University of Alabama Botanical Center Seminar Series, Purdue University; February 4, 2003. LaFayette, IN.

Djousse L, Rothman KJ, Cupples LA, Arnett DK, Ellison RC. Relation between serum albumin and carotid atherosclerosis the NHLBI family heart study. Stroke. 2003 Jan 1;34(1):53-7.

Hawe E, Talmud PJ, Miller GJ, Humphries SE, Northwick Park Heart Study . Second Northwick Park Heart Study. Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study. Ann Hum Genet. 2003;67(Pt 2):97-106.

Doughty N, McKenna SP, Meads D, Doward LC, Pepke-Zaba J. Interim validation studies of new quality of life (QOL) and health-related quality of life (HRQL) measures specific to pulmonary arterial hypertension (PAH). Thorax. 2003;58(S3):84.

Robertson KS, Hawe E, Miller GJ, Talmud PJ, Humphries SE, Northwick Park Heart Study II . Northwick Park Heart Study II. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta. 2003;1639(3):203-12.